Illumina Sequencing Revenue Grows 70 Percent in Q4, Driven by HiSeq

During a conference call to discuss the company's earnings, Illumina representatives outlined plans for the MiSeq platform, Epicentre products, and refurbished Genome Analyzers.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.